Scientific founders of seed companies often do not have the expertise, capabilities, and/or time for all the critical aspects in turning science into a business. Their primary focus, as leading experts, should be on their key strength – advancing science.

However, the harsh reality of today’s economic environment is that science alone is not enough for funding. Venture firms need to see science aligned with a commercially viable strategic vision and the operational capacity to execute.

Ex³ helps startups that are struggling with operational decisions – from hiring C-suite executives, to figuring out a company’s IT and administrative needs, Ex³ accelerates companies from Seed funding to the next round of funding through IPO.

At Ex³, we understand the unique challenges faced by early-stage biotech companies. We have worked with numerous startups, witnessing journeys from conception to commercialization. Our extensive knowledge and hands-on approach offer solutions tailored to your needs, ensuring success at every step of the way.

Ex³ by Portal Innovations is led by Ritu Shah, an industry veteran with an impressive 25+ years of experience at Shire, AveXis, Levo Therapeutics, and Pyxis Oncology. Joined by Karol Sokolowski, bringing 10+ years of translational biomedical R&D, strategic consulting, and clinical experience, our team brings unparalleled expertise and insights to help your biotech thrive.

Other companies we help include, Grove Biopharma, Angstrom Insights, OrisDx, ImmuneBro, CardioSense, Acorn Genetics, Rhaeos, Schedule1 Therapeutics.

Please reach out to karol.sokolowski@portalinnovations.com.